BIOXYTRAN, INC 8-K

What Happened
Bioxytran, Inc. (NASDAQ: BIXT) filed an 8-K on February 17, 2026 disclosing that on February 10, 2026 it entered into a commercial Distribution Agreement with Khoury Medical LTD. Under the agreement Khoury Medical will commercialize A-SUQAR®, a chewable dietary supplement that contains Bioxytran’s proprietary partially hydrolyzed guar gum (PHGG) formulation, in permitted markets. The product is marketed as a supplement intended to support healthy post-meal blood sugar levels in accordance with applicable regulatory requirements.

Key Details

• Agreement date: February 10, 2026; 8-K filed February 17, 2026.
• Partner: Khoury Medical LTD, a company focused on development and commercialization of plant-derived dietary supplements.
• Product: A-SUQAR® chewable dietary supplement containing Bioxytran’s PHGG formulation.
• Filing notes: The Distribution Agreement is attached as Exhibit 10.90 and a press release is attached as Exhibit 99.1. The filing does not disclose financial terms or exclusivity/territory specifics.

Why It Matters
This agreement establishes a commercial pathway for Bioxytran’s PHGG-based product, potentially expanding market reach and creating a route to generate product sales outside of Bioxytran’s direct channels. For investors, the filing signals a move toward commercialization of a science-based ingredient but provides no financial details, timelines, or sales forecasts—so the immediate financial impact is unclear. Monitor future filings or company updates for sales figures, territory scope, and any disclosed financial terms.